Sign in
Taking people in United StatesPhase 1

ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

Key facts

Who runs it
Immusoft of CA, Inc.
Where
Minneapolis and Oakland, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
11 people, planned
Started
12 Apr 2023
Expected to end
1 Jun 2044
Type of study
Interventional, 2 groups
Treatments tested
  • Autologous Plasmablasts (B cells)
Record updated
17 July 2026

Who can take part

Age
10 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome
  • Age ≥ 10 years at time of study registration
  • Creatinine clearance, calculated or measured directly, that is >60ml/min/1.73m2
  • Ejection fraction ≥ 40% by echocardiogram
  • Must commit to traveling to the study site for the necessary follow-up evaluations
  • Must agree to stay <45-minute drive from the study site for a minimum of 5 days after cell infusion

Who cannot take part

  • Underwent a previous hematopoietic stem cell transplant (HSCT)
  • Known familial inherited cancer syndrome. Suspected cases will be investigated, per the physicians discretion, using relevant genetic tests to determine presence of germline mutations
  • History of B cell related cancer, EBV lymphoproliferative disease or autoimmune disorders
  • Evidence of active graft-vs-host disease
  • Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment
  • Requirement for systemic immune suppression
  • Requirement for continuous supplemental oxygen
  • In the investigator's judgement, the subject is unlikely to complete all protocol-required study visits or procedures, including follow up visits, or comply with the study requirements for participation; Other protocol defined inclusion/exclusion criteria may apply

This trial is currently available in United States.

  • University of MinnesotaMinneapolis, United StatesContact: Paul Orchard, MD (principal investigator)Taking people
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Daniel SchraderTaking people

About the trial

What the trial wants to find out

A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.

The 2 groups in the trial

  • Autologous Plasmablasts (B cells) - Cohort - Target Dose ATreatment being tested

    Dose Level: 5 x 10e7 cells/kg on Day 0

    Treatment: Autologous Plasmablasts (B cells)

  • Autologous Plasmablasts (B cells) - Cohort - Target Dose BTreatment being tested

    Dose Level: Between 1 x 10e8 or to 2 x 10e8 cells/kg on Day 0

    Treatment: Autologous Plasmablasts (B cells)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie
Record updated
17 July 2026